2. Search Result
Search Result
Results for "

Rec-1

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136250
    BSJ-03-204

    		PROTACs CDK Cancer
    BSJ-03-204 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC50s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity [1].
    BSJ-03-204
  • HY-136250A
    BSJ-03-204 triTFA

    		PROTACs CDK Cancer
    BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC50s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 triTFA does not induce IKZF1/3 degradation and has anti-cancer activity [1].
    BSJ-03-204 triTFA
  • HY-148683
    EG-011

    		Arp2/3 Complex Cancer
    EG-011 is the first-in-class and potent Wiskott-Aldrich syndrome protein (WASP) activator. EG-011 activates the auto-inhibited form of WASP with strong actin polymerization. EG-011 has selective anti-tumor activity in lymphomas [1] .
    EG-011
  • HY-137471
    RBPJ Inhibitor-1
    5 Publications Verification

    RIN1

    		 Notch Cancer
    RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation [1].
    RBPJ Inhibitor-1
  • HY-172430S
    Epaldeudomide

    		TNF Receptor Cancer
    Epaldeudomide (Compound A406) is the inhibitor for TNF-α (>50% inhibition rate at 100 nM). Epaldeudomide inhibits the proliferation of cancer cells MM.1S (IC50 < 300 nM), WSU-DLCL-2 (IC50 < 100 nM) and Rec-1 (IC50 < 100 nM). Epaldeudomide exhibits antineoplastic activity [1].
    Epaldeudomide
  • HY-174850
    CFON-026

    		Btk Cancer
    CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27  nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L). CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia [1].
    CFON-026
  • HY-RS11596
    RAD1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RAD1 Human Pre-designed siRNA Set A contains three designed siRNAs for RAD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RAD1 Human Pre-designed siRNA Set A
    RAD1 Human Pre-designed siRNA Set A
  • HY-174129
    TM471-1

    		Btk Apoptosis Cancer
    TM471-1 is an orally active and covalent Bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 1.3 nM (BTK WT), >40,000 nM (BTK C481S), 7.9 nM (TEC) and 12.4 nM (TXK). TM471-1 inhibits cell growth in vivo and in vitro, arrests cell cycle at G0/G1 phase and induces cell apoptosis [1].
    TM471-1
  • HY-RS20597
    Slc7a1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Slc7a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Slc7a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Slc7a1 Mouse Pre-designed siRNA Set A
    Slc7a1 Mouse Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: